Related Experiment Videos
Pediatric asthma: "Real world" measures of effectiveness
1Department of Allergy, Immunology, and Pulmonary Medicine, Children's National Medical Center, George Washington University School of Health Science, Washington, DC, USA. rfink@cnmc.org
Pediatric Pulmonology. Supplement
|July 28, 2001
Summary
Assessing pediatric asthma interventions requires careful consideration of cost-effectiveness and therapeutic value. Long-term trials measuring real-world outcomes, including patient quality of life and adherence, are crucial for accurate evaluation.
Area of Science:
- Pediatric Pulmonology
- Health Economics
- Clinical Trial Design
Background:
- Evaluating pediatric asthma interventions presents challenges in measuring cost-effectiveness and therapeutic value.
- Variability in asthma symptoms, patient selection biases, and outcome assessment in children complicate trial validity.
- Real-world conditions, broad-based outcomes, and long-term quality of life are essential for effective asthma intervention assessment.
Purpose of the Study:
- To provide guidance on properly assessing the cost and therapeutic value of pediatric asthma interventions.
- To highlight key parameters for determining cost-effectiveness in pediatric asthma treatment.
- To emphasize the importance of real-world data and long-term evaluation in clinical trials.
Main Methods:
- Discussion of challenges in pediatric asthma clinical trials, including patient selection and outcome measurement.
- Emphasis on incorporating objective pulmonary function and subjective quality-of-life measures.
- Consideration of patient adherence as a critical variable influenced by drug characteristics and quality of life.
Main Results:
- Cost-effectiveness and therapeutic value assessment in pediatric asthma are complex.
- Subtle biases and variable symptomatology can impact measurement validity.
- Long-term, real-world data including patient adherence and quality of life are vital.
Conclusions:
- Accurate assessment of pediatric asthma interventions necessitates long-term, real-world data.
- Patient adherence and quality of life significantly influence treatment effectiveness.
- Comprehensive evaluation requires broad-based outcome measures in clinical trials.